Haemonetics (NYSE:HAE) Upgraded at StockNews.com

StockNews.com upgraded shares of Haemonetics (NYSE:HAE) from a hold rating to a buy rating in a report released on Monday.

Other research analysts also recently issued reports about the stock. Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. Raymond James reissued a “strong-buy” rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Barrington Research decreased their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. JMP Securities lowered their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, February 7th. Finally, Needham & Company LLC cut their price objective on Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Trading Down 2.0 %

NYSE:HAE opened at $62.59 on Monday. The company has a market cap of $3.14 billion, a P/E ratio of 24.64, a P/E/G ratio of 1.11 and a beta of 0.41. Haemonetics has a 1 year low of $55.30 and a 1 year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The stock’s fifty day moving average price is $62.69 and its two-hundred day moving average price is $71.59.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, analysts expect that Haemonetics will post 4.55 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Boston Trust Walden Corp grew its holdings in shares of Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock valued at $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Empowered Funds LLC purchased a new stake in Haemonetics during the fourth quarter valued at about $319,000. Pacer Advisors Inc. grew its stake in shares of Haemonetics by 36.1% during the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier’s stock valued at $789,000 after buying an additional 2,680 shares during the last quarter. Norges Bank purchased a new position in shares of Haemonetics in the fourth quarter worth about $32,803,000. Finally, Voya Investment Management LLC lifted its stake in shares of Haemonetics by 820.5% in the 4th quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier’s stock valued at $24,748,000 after acquiring an additional 282,521 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.